Nuvectis Pharma (NVCT) said Wednesday it has priced an underwritten public offering of 2.7 million of its shares at $5.00 apiece to raise $13.5 million.
Nuvectis said it has also granted its underwriter a 30-day option to buy up to 405,000 additional shares. It expects to close the offering Feb. 6, with Lucid Capital Markets as the book runner.
The proceeds will be used among others to advance its development programs, for capital expenditures, and other general corporate purposes, the clinical-stage company said.
The shares were up over 6% in recent trading.
Price: 7.48, Change: +0.48, Percent Change: +6.86
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。